#1 Clinical Trials Search in Europe

Fludeoxyglucose (18F)

Fludeoxyglucose (18F), also known as FDG, is a radioactive drug used in medical imaging, particularly in PET/CT scans. This article explores its use in clinical trials for various types of cancer, including pancreatic, lung, breast, and head and neck cancers. We’ll discuss how this imaging agent is being utilized to improve diagnostic accuracy, treatment planning, and assessment of therapy effectiveness in cancer patients.

Table of Contents

What is Fludeoxyglucose (18F)?

Fludeoxyglucose (18F), also known as 18F-FDG, FDG, or fluorodeoxyglucose (18F), is a special type of drug used in medical imaging[1]. It’s not a treatment drug, but rather a diagnostic tool that helps doctors see what’s happening inside your body[2].

How It Works

Fludeoxyglucose (18F) is used in a type of imaging called PET/CT, which stands for Positron Emission Tomography/Computed Tomography[1]. This is a sophisticated scanning technique that combines two types of images to give doctors a detailed look at your body’s structures and functions.

When you receive Fludeoxyglucose (18F), it travels through your body and is absorbed by cells that are using a lot of energy, such as cancer cells. The drug is slightly radioactive, which allows the PET scanner to detect where it has accumulated in your body[2].

Medical Uses

Fludeoxyglucose (18F) is used to help diagnose and monitor several conditions:

  • Cancer: It’s particularly useful in detecting and monitoring certain types of cancer, including:
    • Non-small cell lung cancer
    • Breast cancer
    • Head and neck cancer
  • Inflammation: It can help identify areas of inflammation in the body[2].
  • Pancreatic Cancer: In some studies, it’s used to help plan treatment for pancreatic cancer[1].

Administration

Fludeoxyglucose (18F) is given as a single intravenous (IV) injection. The dose is calculated based on each patient’s needs and the specific purpose of the scan[1][2]. After the injection, you’ll need to wait for a short period before the scanning begins, to allow the drug to distribute throughout your body.

Safety and Monitoring

While Fludeoxyglucose (18F) is generally considered safe, doctors carefully monitor patients after administration. This monitoring typically includes:

  • Vital signs: Doctors will check your ECG (a test that measures your heart’s electrical activity), blood pressure, heart rate, and body temperature[2].
  • Blood tests: These may include serum chemistry, clotting status, and hematology (blood cell counts)[2].
  • Adverse event collection: Doctors will keep track of any side effects or unexpected reactions[2].

These checks are typically done at least twice within 8 days after the procedure[2].

Aspect Details
Primary Use of Fludeoxyglucose (18F) Diagnostic imaging in PET/CT scans for cancer detection and monitoring
Cancer Types Studied Pancreatic, Non-small cell lung, Breast, Head and neck
Role in Treatment Planning Used for precise targeting in stereotactic body radiotherapy (SBRT)
Comparison Studies Evaluated against other tracers like BAY86-9596 for diagnostic performance
Safety Monitoring Vital signs, blood tests, adverse event reporting
Outcome Measures Tumor detection rate, quantitative uptake analysis (SUVs), progression-free survival, overall survival

FAQ

  • What is Fludeoxyglucose (18F) and how is it used in cancer imaging? Fludeoxyglucose (18F), or FDG, is a radioactive drug used in PET/CT scans. It helps doctors see how active cancer cells are in the body, as these cells tend to use more glucose (sugar) than normal cells. This allows for better detection and monitoring of cancer.
  • In which types of cancer is Fludeoxyglucose (18F) being studied? The clinical trials mentioned in this article are studying the use of Fludeoxyglucose (18F) in various cancers, including pancreatic cancer, non-small cell lung cancer, breast cancer, and head and neck cancer.
  • How does Fludeoxyglucose (18F) help in radiation therapy planning? In the pancreatic cancer study, FDG-PET/CT scans are used for treatment planning in stereotactic body radiotherapy (SBRT). This helps doctors accurately target the tumor while minimizing damage to surrounding healthy tissue.
  • Are there any side effects associated with Fludeoxyglucose (18F)? The clinical trials monitor for potential side effects through various measures, including vital signs, blood tests, and adverse event reporting. However, FDG is generally considered safe when used as directed for diagnostic imaging purposes.
  • How does Fludeoxyglucose (18F) compare to other imaging tracers? One of the studies compares the performance of Fludeoxyglucose (18F) with another tracer called BAY86-9596 in cancer detection. This comparison helps researchers understand the strengths and limitations of different imaging agents in diagnosing and monitoring cancer.

Ongoing Clinical Trials on Fludeoxyglucose (18F)

  • Study on Aortic Stenosis: Evaluating Fludeoxyglucose (18F) for Patients with Conduction Disorders After Aortic Valve Procedures

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effectiveness and Safety of Nemtabrutinib for Patients with Blood Cancers, Including CLL, SLL, MCL, MZL, FL, and Waldenström’s Macroglobulinemia

    Recruiting

    1 1 1
    Investigated drugs:
    Czechia Denmark France Germany Hungary Ireland +4

  • Study Comparing FDG-PET/CT and CT for Monitoring Treatment Response in Patients with Metastatic Breast Cancer Using Fludeoxyglucose (18F)

    Recruiting

    1 1 1 1
    Investigated drugs:
    Denmark Germany Italy

  • Study of FLUDEOXYGLUCOSE (18F) PET Imaging of Brain Metabolism in Patients with Persistent Post‑COVID Syndrome

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    The Netherlands

  • Using fludeoxyglucose (18F) in PET/CT imaging to diagnose and monitor cardiovascular device infections

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • A study comparing 68Ga-FAPI-46 PET scan with standard 18F-FDG PET scan and brain MRI for staging in patients with newly diagnosed non-small cell lung cancer

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on the Use of PET Scans with Fludeoxyglucose (18F) for Diagnosing Endometriosis in Patients with Symptoms

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Safety and Tolerability Study of AB-1001 Brain Injection in Adults with Early Huntington’s Disease

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Monitoring Metastatic Breast Cancer Response Using Fludeoxyglucose (18F) PET/CT for Patients with Metastatic Breast Cancer

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Denmark

  • Study on the Accuracy of 68Ga-FAPI-46 and Fludeoxyglucose (18F) PET/CT Scans for Staging and Restaging in Patients with Ovarian Cancer

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

Glossary

  • PET/CT: Positron Emission Tomography/Computed Tomography, a combined imaging technique that provides detailed information about both the structure and function of cells and tissues in the body.
  • Stereotactic Body Radiotherapy (SBRT): A highly precise form of radiation therapy that delivers high doses of radiation to specific areas of the body, often used to treat small, well-defined tumors.
  • Fiducials: Small, marker objects placed in or near a tumor to help guide radiation therapy by providing a reference point for targeting.
  • Gemcitabine: A chemotherapy drug commonly used to treat various types of cancer, including pancreatic cancer.
  • Standardized Uptake Values (SUVs): A measurement used in PET imaging to quantify the uptake of a radioactive tracer in body tissues, helping to assess the activity of tumors or other abnormalities.
  • Progression-Free Survival: The length of time during and after treatment that a patient lives without the cancer getting worse.
  • Freedom From Local Progression (FFLP): A measure of how long a patient remains free from cancer growth at the original tumor site after treatment.
  • Gastrointestinal Toxicity: Side effects that affect the digestive system, such as nausea, vomiting, or diarrhea, which can occur as a result of cancer treatments.

References

  1. https://clinicaltrials.gov/study/NCT01146054
  2. https://clinicaltrials.gov/study/NCT01089998